Ten years after the beginning of Crimean-Congo hemorrhagic fever outbreak in Iran: A promising report

Iranian Journal of Clinical Infectious Diseases

Volumn 4, Issue 3, 2009, Pages 189-193

  Sharifi Mood, Batool ^a   Alavi Naini, Roya ^a   Metanat, Maliheh ^a  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN;

BIOSAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; HEALTH HAZARD; HUMAN; INFECTION RISK; IRAN; LEUKOCYTOSIS; NAIRO VIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; THROMBOCYTOPENIA; VIRUS HEMORRHAGIC FEVER;

EID: 77953474763     PISSN: 17355109     EISSN: 20081081     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Mardani M, Keshtkar Jahromi M, Holakouie Naieni Kand M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. CID 2003;36:1613-18.
2. Chinikar S, Goya MM, Shirzadi R, Ghiasi SM, Mirahmadi R. Surveillance and laboratory detection system of Crimean-Congo haemorrhagic fever in Iran. Transboundary and Emerging Diseases 2008;(55):200-4.
3. Sharifi-Mood B, Alavi-naini R, Metanat M, Rakhshani F. Ribavirin: an effective drug for treatment of children wit Crimean-Congo hemorrhagic fever :A seven years experiences. Pak J Biolo Sci 2006; 9(8):1598-60.
4. Izadi S, Salehi M, Holakouie-Naieni K, Chinikar S. The risk of transmission of Crimean-Congo hemorrhagic fever virus from human cases to first-degree relatives. Jpn J Infect Dis 2008;61(6):494-6.
5. Ardalan MR, Tubbs RS, Chinikar S, Shoja MM. Crimean-Congo haemorrhagic fever presenting as thrombotic microangiopathy and acute renal failure. Nephrol Dial Transplant 2006;21(8):2304-7.
6. Metanat M, Sharifi-Mood B. The epidemiological aspect of Crimean-Congo hemorrhagic fever in southeast of Iran. J Med Sci 2006;6(2):213-15.
7. Mardani M, Keshtkar-Jahromi M, Ataie B, Adibi P. Crimean-Congo hemorrhagic fever virus as a nosocomial pathogen in Iran. Am J Trop Med Hyg 2009;81(4):675-8.
8. Mardani M, Rahnavardi M, Rajaeinejad M, Naini KH, Chinikar S, Pourmalek F, et al. Crimean-Congo hemorrhagic fever among health care workers in Iran: a seroprevalence study in two endemic regions. Am J Trop Med Hyg 2007;76(3):443-5.
9. Alavi-Naini R, Moghtaderi A, Kouhpayeh H, Sharifi-Mood B. Crimean-Congo hemorrhagic fever in southeast of Iran. J Infection 2006;52:378-82.
10. Metanat M, Sharifi-Mood B, Salehi M. Efficacy of oral ribavirin in the treatment of CCHF. Abstract book of the 24th Congress of ICC in Philippines. June 2005. p: 32.
11. Sharifi-Mood B, Metanat M, Ghorbani-Vaghei A, Fayyaz-Jahani F, Akrami E. The outcome of patients with Crimean-Congo hemorrhagic fever in Zahedan, Southeast of Iran: A comparative study. Arch Iranian Med 2006;12(2):151-53.
12. Izadi S, Salehi M. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo haemorrhagic fever patients: A case-control study. Jpn J Infect Dis 2009;62:11-15.
13. Sharifi-Mood B, Mardani M, Keshtkar-Jahromi M, Rahnavardi M, Hatami H, Metanat M. Clinical and epidemiological features of CCHF among children and adolescents from southeastern Iran. Pediatr Infect Dis J 2008;27(6):555-58.
14. Sharifi Mood B, Mardani M, Metanat M. Clinical manifestations, laboratory findings and clinical outcome in 6 pregnant women with Crimean-Congo hemorrhagic fever. Iran Journal of Clinical Infectious Diseases 2007;2(4):193-96.
15. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, Khurshid M, McCormick JB. Crimean-Congo haemorrhagic fever treated with oral ribavirin. Lancet 1995;346:472-5.
16. CDC Update. Management of patients with suspected viral haemorrhagic fever. MMWR Morb Mortal Wkly Rep 1995;44:475-9.
17. Watts DM, Ussery MA, Nash D, Peters CJ. Inhibition of Crimean-Congo haemorrhagic fever viral infectivity yields in-vitro by ribavirin. Am J Trop Med Hyg 1989;41:591-5.
18. Sheikh AS, Sheikh AA, Sheikh SK, Tariq M. Ribavirin: an effective treatment of CCHF. Pak Med Sci 2004;3:201-6.
19. Mirazimi A. Old and new treatment strategies. In: Ergonul O, Whitehouse CA, editors. Crimean-Congo hemorrhagic fever: a global perspective. Springer, Dordrecht, NL. 2007;p:258-60.
20. Huggins JW, Hsiang CM, Cosgriff TM, Guang MY, Smith JI, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991;164:1119-27.
21. Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res 2004;64:145-60.
22. Whitehouse CA. Risk groups and control measures for Crimean Congo hemorrhagic fever. In: Ergonul O, Whitehouse CA, editors. Crimean- Congo hemorrhagic fever: a global perspective. Springer, Dordrecht, NL. 2007;p:273-80.
23. Vatansever Z, Uzun R, Estrada-Pena A, Ergonul O. Crimean-Congo hemorrhagic fever in Turkey. In: Ergonul O, Whitehouse CA, editors. Crimean- Congo hemorrhagic fever: a global perspective. Springer, Dordrecht, NL. 2007;p:59-74.
24. Watts DM, Ussery MA, Nash D, Peters CJ. Inhibition of Crimean- Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop Med Hyg 1989;41:581-85.
25. Metanat M, Sharifi-Mood B, Salehi M, Alavi-Naini R. Clinical outcomes in Crimean-Congo hemorrhagic fever: A five-years experience in the treatment of patients in oral Ribavirin. Intl J Virol 2006;2(1):21-24.
26. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res 2008;78:125-31.
27. Moghtaderi A, Alavi-Naini R, Azimi H. Compartment syndrome: an unusual course for a rare disease. Am J Trop Med Hyg 2005;73(2):450-2.
28. Mardani M, Keshtkar-Jahromi M. Crimean-Congo hemorrhagic fever. Arch Iran Med 2007;10(2)::204-14.